Pacira BioSciences (PCRX) revenue breakdown
By product, Net product sales is the largest at 100% of fiscal 2025 revenue, growing 11% a year over 5 years.
Revenue by product
Fiscal years, as Pacira BioSciences reports them in its 10-K filings; fiscal 2025 total $726M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | — | — | — | — | $427M | $539M | $664M | $672M | $697M | $723M | 100% |
| Royalty revenue | — | — | — | — | $3M | $2M | $3M | $3M | $4M | $4M | 0% |
| EXPAREL | $266M | $283M | $331M | $408M | — | — | — | — | — | — | — |
| iovera° | — | — | — | $8M | — | — | — | — | — | — | — |
| Bupivacaine liposome injectable suspension | — | — | — | $3M | — | — | — | — | — | — | — |
| Other product sales | $4M | — | $1M | — | — | — | — | — | — | — | — |
| DepoCyte | — | $1M | — | — | — | — | — | — | — | — | — |
| Collaborative licensing and milestone revenue | — | — | — | — | — | $125,000 | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PCRX.
Open PCRX in InvestinglyQuestions
Where does Pacira BioSciences make its money?
In fiscal 2025, by product: Net product sales $723M, Royalty revenue $4M.
From Pacira BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.